News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immune Targeting Systems (ITS) Ltd. Confirms Industry Heavyweight Ken Powell as New Chairman



11/16/2009 10:27:44 AM

LONDON--(BUSINESS WIRE)--Immune Targeting Systems (ITS) Ltd, whose synthetic universal influenza-A vaccine enters clinical trials in 2010, today announced that Ken Powell has joined the board as non-executive Chairman. Ken was formerly CEO of Arrow Therapeutics which he led to a successful trade sale to Astra-Zeneca in 2007. The Company also announced the appointment of Dr. Campbell Bunce, formerly Development Director at Piramed, as R&D Director.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES